Evidence map›Paper›PMID 38672179›Full record

ArticleBiomedicines2024

Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study.

Jessica Cusato, Davide Giuseppe Ribaldone, Michela Helga Falzone, Alessandra Manca, Miriam Antonucci, Alice Palermiti, Giorgio Maria Saracco, Linda Ceccarelli, Francesco Costa, Andrea Bottari and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jessica CusatoLaboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Corso Svizzera, 164, 10149 Turin, Italy.ORCID 0000-0003-1977-9694
Davide Giuseppe RibaldoneUnit of Gastroenterology, Department of Medical Sciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0002-9421-3087
Michela Helga FalzoneUnit of Gastroenterology, Department of Medical Sciences, University of Turin, 10124 Turin, Italy.ORCID 0009-0004-6911-7327
Alessandra MancaLaboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Corso Svizzera, 164, 10149 Turin, Italy.ORCID 0000-0002-8540-6709
Miriam AntonucciSCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, 10149 Turin, Italy.
Alice PalermitiLaboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Corso Svizzera, 164, 10149 Turin, Italy.ORCID 0000-0003-0860-280X
Giorgio Maria SaraccoUnit of Gastroenterology, Department of Medical Sciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0001-5310-4143
Linda CeccarelliIBD Unit, Department of General Surgery and Gastroenterology, Pisa University Hospital, 56124 Pisa, Italy.
Francesco CostaIBD Unit, Department of General Surgery and Gastroenterology, Pisa University Hospital, 56124 Pisa, Italy.ORCID 0000-0002-9150-3345
Andrea BottariGastroenterology Unit, University of Pisa, 56126 Pisa, Italy.
Ginevra FornaroliGastroenterology Unit, University of Pisa, 56126 Pisa, Italy.
Gian Paolo CavigliaSCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, 10149 Turin, Italy.ORCID 0000-0002-0529-9481
Antonio D'AvolioLaboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Corso Svizzera, 164, 10149 Turin, Italy.ORCID 0000-0002-1321-4126
Lorenzo BertaniIBD Unit, Department of General Surgery and Gastroenterology, Pisa University Hospital, 56124 Pisa, Italy.
Ospedale Amedeo di Savoia · ITUniversity of Turin · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the years, vedolizumab (VDZ) has emerged as a more effective target therapy for inflammatory bowel disease. The aim of this work was to analyze a cohort of inflammatory bowel disease patients, evaluating the association between VDZ serum concentrations at 6 months from starting therapy and their clinical and biochemical indexes within one year of treatment, correlating drug levels with response and clinical remission. Forty patients treated with VDZ were enrolled. Drug concentrations were quantified through ELISA methods. VDZ levels correlated with hemoglobin levels at twelve months of therapy (

Indexed as

IBDmonoclonal antibodypersonalized therapyTDM

Identifiers

PMID38672179
PMCPMC11048400
OpenAlexW4394619246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.